{"id":62994,"date":"2026-04-23T19:02:23","date_gmt":"2026-04-23T17:02:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/"},"modified":"2026-04-23T19:02:23","modified_gmt":"2026-04-23T17:02:23","slug":"median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/","title":{"rendered":"Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\neyonis\u00ae LCS 510(k) clearance sets stage for commercialization in the United States<\/li>\n<li>\nNew leadership of U.S. subsidiary and collaboration with Tempus accelerate rollout<\/li>\n<li>\n28% reduction in operating loss in 2025 year\u2011over\u2011year, demonstrating strengthened cost discipline and operational efficiency<\/li>\n<li>\niCRO order backlog reaches a new record at \u20ac79.8 million as of March 31, 2026<\/li>\n<li>\nCash and cash equivalents of \u20ac14.0 million as of March 31, 2026<\/li>\n<li>\nCash runway through year\u2011end 2026, with potential for further extension subject to the exercise of 2025 warrants, representing up to \u20ac44.4 million in additional proceeds<\/li>\n<\/ul>\n<p>SOPHIA ANTIPOLIS, France&#8211;(BUSINESS WIRE)&#8211;Regulatory\u00a0News:<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260423130605\/en\/2783697\/5\/Logo_Median.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260423130605\/en\/2783697\/22\/Logo_Median.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260423130605\/en\/2783697\/5\/Logo_Median.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260423130605\/en\/2783697\/21\/Logo_Median.jpg\"><\/a><\/p>\n<p>\nMedian Technologies <i>(FR0011049824, ALMDT, \u201cMedian\u201d or the \u201cCompany\u201d)<\/i>, developer of eyonis\u00ae, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-powered and central imaging services for oncology drug developers, today reported its 2025 consolidated annual financial results, and provided key business highlights (unaudited) for the first quarter of 2026. The consolidated financial statements for the financial year ended December 31, 2025, were audited and approved by the Company\u2019s Board of Directors on April 22, 2026.<\/p>\n<p>\n<b>Fredrik Brag, CEO and Founder of Median Technologies, commented:<i> <\/i><\/b><i>\u201cMedian Technologies began 2026 with a transformational milestone, securing U.S. FDA 510(k) clearance for eyonis\u00ae LCS and accelerating commercialization efforts to support and scale lung cancer screening programs\u2014delivering a major advance in cancer care by enabling the diagnosis of lung cancer at a stage when it can be cured. Oran Muduroglu, named President of our U.S. subsidiary Median eyonis Inc., brings extensive experience of translating technical innovation into broad U.S. adoption and we have concluded a collaboration with Tempus to expand access. We also anticipate a decision on CE marking for eyonis\u00ae LCS in the second quarter of 2026, a key regulatory milestone toward broader market access.<\/i><\/p>\n<p>\n<i>The foundation for this momentum was a year of disciplined execution and tangible progress for Median Technologies in 2025, marked by a 28% year\u2011over\u2011year reduction in operating loss while continuing to invest in our strategic priorities. The record \u20ac79.8 million iCRO order backlog highlights the strength and visibility of our business.<\/i><\/p>\n<p>\n<i>Our cash position of \u20ac14.0 million as of March 31, 2026 supports the execution of our strategic priorities<\/i><i>\u2014<\/i><i>including the ramp-up of U.S. commercialization of eyonis\u00ae LCS and the anticipated CE marking decision<\/i><i>\u2014<\/i><i>providing a cash runway through year\u2011end 2026 and beyond, with the potential for further extension subject to the exercise of 2025 warrants, representing up to approximately \u20ac44 million in additional proceeds.\u201d<\/i><\/p>\n<p>\n<b>Q1 2026 Operational and Financial Update (unaudited)<\/b><\/p>\n<p>\n<b>eyonis\u00ae LCS Software as a Medical Device: AI-driven Innovation for Lung Cancer Screening<\/b><\/p>\n<p>\n<span class=\"bwuline\">Q1 2026 Key Achievements<\/span><\/p>\n<p>\nMedian Technologies successfully executed on key strategic milestones in the first quarter of 2026, significantly advancing its readiness for the commercial launch of eyonis\u00ae LCS in the United States.<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmediantechnologies.com%2Finvestors%2Fpress-releases%2Fmedian-technologies-receives-fda-510k-clearance-for-eyonis-lcs-the-first-ai-tech-based-detection-and-diagnosis-device-for-lung-cancer-screening%2F&amp;esheet=54521559&amp;newsitemid=20260423130605&amp;lan=en-US&amp;anchor=On+February+9%2C+2026%2C&amp;index=1&amp;md5=ce65cbdc7a3a5e1a0f3a21ca05cb8307\" rel=\"nofollow\" shape=\"rect\">On February 9, 2026,<\/a> Median Technologies announced that it has received FDA 510(k) clearance for eyonis\u00ae LCS, the first AI\u2011based device for the detection and diagnosis of lung cancer in screening programs. eyonis\u00ae LCS uniquely combines detection and characterization of lung cancer on low\u2011dose CT scans, with 93.3% sensitivity, 92.4% specificity and a 99.9% negative predictive value (manufacturer performance testing on a lung cancer screening reference population). U.S. authorization is expected to enable large\u2011scale deployment of lung cancer screening programs for the approximately 14.5 million eligible individuals nationwide, supported by a clear and predictable reimbursement pathway through the existing NT\u2011APC 1508 code with current reimbursement set at approximately USD 650 per procedure.<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmediantechnologies.com%2Finvestors%2Fpress-releases%2Fmedian-technologies-announces-collaboration-with-tempus-to-expand-access-to-eyonis-lcs-software-as-a-medical-device-in-the-united-states%2F&amp;esheet=54521559&amp;newsitemid=20260423130605&amp;lan=en-US&amp;anchor=On+February+12%2C+2026%2C&amp;index=2&amp;md5=3741341ee75da253b59d94b394ab4144\" rel=\"nofollow\" shape=\"rect\">On February 12, 2026,<\/a> Median Technologies announced collaboration with <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tempus.com%2F&amp;esheet=54521559&amp;newsitemid=20260423130605&amp;lan=en-US&amp;anchor=Tempus+AI&amp;index=3&amp;md5=6ebd8c9012bf2553b685534f34f105b2\" rel=\"nofollow\" shape=\"rect\">Tempus AI<\/a>, Inc. (NASDAQ: TEM), a U.S. technology company leading the adoption of AI to advance precision medicine, to expand access to eyonis\u00ae LCS Software as a Medical Device in the United States. The non-exclusive distribution agreement leverages Tempus\u2019 established position in oncology and AI-based precision medicine, and its strong network of healthcare providers, oncologists, and diagnostic centers. Under the distribution agreement, eyonis\u00ae LCS will be integrated into the clinical workflow through the Tempus Pixel platform. Tempus AI would also support the commercial rollout of eyonis\u00ae LCS across Europe, after the achievement of eyonis\u00ae LCS CE marking.<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmediantechnologies.com%2Finvestors%2Fpress-releases%2Ffda-clearance-sets-stage-for-u-s-commercialization-of-eyonis-lcs-software-as-a-medical-device-for-lung-cancer-screening-oran-muduroglu-appointed-president-of-median-eyonis-inc%2F&amp;esheet=54521559&amp;newsitemid=20260423130605&amp;lan=en-US&amp;anchor=On+February+18%2C+2026%2C&amp;index=4&amp;md5=bac2dcd0e8fa800ae971cab107460173\" rel=\"nofollow\" shape=\"rect\">On February 18, 2026,<\/a> Median Technologies announced the naming of Oran Muduroglu as President of Median eyonis Inc., the Company\u2019s U.S. subsidiary responsible for the commercial deployment of eyonis\u00ae LCS in the United States. A seasoned medical technology entrepreneur, Oran Muduroglu will lead the U.S. commercial rollout of eyonis\u00ae LCS. He brings more than three decades of experience designing, building, and scaling enterprise imaging and clinical workflow platforms, with a proven track record of translating complex technological innovation into broad adoption across the U.S. healthcare market.<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmediantechnologies.com%2Finvestors%2Fpress-releases%2Fmedian-technologies-achieves-iso-134852016-certification-for-eyonis-medical-device-quality-management-system%2F&amp;esheet=54521559&amp;newsitemid=20260423130605&amp;lan=en-US&amp;anchor=On+March+18%2C+2016&amp;index=5&amp;md5=e5f8f60e1d15c28164b6c0fea0f96108\" rel=\"nofollow\" shape=\"rect\">On March 18, 2016<\/a>, Median Technologies announced that the eyonis\u00ae Quality Management System has achieved ISO 13485:2016 certification. This key milestone supports the industrialization and global scaling of the eyonis\u00ae portfolio, strengthens the Company\u2019s regulatory pathway, and reinforces Median Technologies\u2019 commitment to delivering safe, reliable, and clinically meaningful oncology solutions.<\/p>\n<p>\n<span class=\"bwuline\">Strategic Outlook and Upcoming Key Milestones<\/span><\/p>\n<p>\nTo support the commercial development of eyonis\u00ae LCS in the United States, Median eyonis Inc. is implementing a comprehensive go\u2011to\u2011market strategy aimed at accelerating adoption and gaining broad market access within lung cancer screening programs. This strategy is built on a multi\u2011channel commercial model that integrates direct enterprise sales, strategic non\u2011exclusive distribution partnerships, and seamless incorporation into established clinical workflows. To execute this strategy, Median eyonis Inc. is actively strengthening its U.S.-based commercial, technological and clinical support infrastructure and engaging with leading U.S. healthcare institutions and networks to establish strategic clinical partnerships that will enable broad and scalable access to eyonis\u00ae LCS nationwide.<\/p>\n<p>\nFollowing the execution of its first non\u2011exclusive eyonis\u00ae LCS distribution agreement with Tempus, Median Technologies is engaged in advanced discussions with several additional industry leaders to further expand its commercial reach across the United States and Europe. The Company is targeting additional non\u2011exclusive distribution agreements with top\u2011tier imaging, cloud technology, and diagnostics partners to support scalable market penetration.<\/p>\n<p>\nThe Company expects the first U.S. sites to be operational in Q3 2026, with first revenue generation by the end of 2026.<\/p>\n<p>\nIn Europe, the Company expects a decision on eyonis\u00ae LCS CE marking in the second quarter of 2026, paving the way for broad adoption and expanded access to potentially hundreds of thousands of patients across European lung cancer screening programs.<\/p>\n<p>\nIn 2026, alongside the commercial rollout of eyonis\u00ae LCS, Median Technologies will continue development of additional SaMD within the eyonis\u00ae portfolio, with a focus on eyonis\u00ae IPN (Incidental Pulmonary Nodules) and eyonis\u00ae HCC (Hepatocellular Carcinoma). The expansion of this portfolio will leverage current commercial efforts and reinforce Median\u2019s global position in early cancer diagnosis based on AI.<\/p>\n<p>\n<b>iCRO: AI-driven and central imaging services for oncology drug development<\/b><\/p>\n<p>\n<span class=\"bwuline\">Q1 2026 Key Achievements<\/span><\/p>\n<p>\nMedian\u2019s order backlog<sup>1<\/sup> and revenue come entirely from the iCRO Business Unit, which provides AI-powered and central imaging services for industry\u2011sponsored oncology clinical trials.<\/p>\n<p>\nAs of March 31, 2026, the Company\u2019s order backlog reached \u20ac79.8 million an all\u2011time high, providing strong revenue visibility over the next several years. This represents an increase of 4.2% compared to December 2025 (\u20ac76.6 million).<\/p>\n<p>\nQ1 2026 revenue totaled \u20ac5.8 million.<\/p>\n<p>\n<span class=\"bwuline\">2026 Strategic Outlook and Key Milestones<\/span><\/p>\n<p>\nMedian\u2019s iCRO business is actively executing its global key account strategy across the three major industry regions\u2014North America, Europe, and Asia.<\/p>\n<p>\nLeveraging its well\u2011recognized expertise in oncology imaging and artificial intelligence, iCRO is well positioned to attract new clients across both large pharmaceutical companies and emerging biotech organizations, while deepening existing relationships by expanding the scope of services supporting drug development.<\/p>\n<p>\nSince late 2025, Median iCRO has expanded its capabilities to provide central imaging services in new therapeutic areas beyond oncology, with a particular focus on central nervous system (CNS) and musculoskeletal (MSK) clinical trials, expanding its addressable market.<\/p>\n<p>\nThe profitability of the iCRO business is expected to continue to increase throughout the rest of 2026, driven by Median\u2019s highly differentiated, high\u2011value imaging technologies and sustained growth in demand for advanced AI\u2011enabled solutions. Furthermore, the progressive integration of AI into imaging project operational workflows\u2014currently under development\u2014is expected to create meaningful operating leverage by enhancing service quality, accelerating project execution, and improving business scalability and overall productivity.<\/p>\n<p>\n<b>Company cash and cash equivalents as of March 31, 2026<\/b><\/p>\n<p>\nAs of March 31, 2026, Median Technologies&#8217; cash and cash equivalents stood at \u20ac14.0 million compared to \u20ac18.2 million as of December 31, 2025.<\/p>\n<p>\nAs of March 31, 2026, a total of 2,044,926 warrants (BSA) has been exercised, out of the 14,424,541 that have been issued in connection with the capital increase completed on August 1, 2025. The exercise of the remaining 12,379,615 warrants would generate additional gross cash proceeds of approximately \u20ac44.4 million, extending the Company\u2019s cash runway well beyond year\u2011end 2026. The warrants are exercisable until January 31, 2028.<\/p>\n<p>\n<b>2025 Financial Highlights (IFRS accounting rules)<\/b><\/p>\n<p>\nOn January 19, 2026, the Company reported key business highlights for fiscal year 2025 and today confirms the following audited figures:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFull\u2011year 2025 revenue of \u20ac23.4 million,<\/li>\n<li>\nOrder backlog reached an all\u2011time high of \u20ac76.6 million as of December 31, 2025, compared to \u20ac66.9 million as of December 31, 2024, reflecting a 7.9% year\u2011over\u2011year increase<\/li>\n<li>\nCash and cash equivalents of \u20ac18.2 million as of December 31, 2025.<\/li>\n<\/ul>\n<p>\n<b>Consolidated statement of cash flows under IFRS accounting rules<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignc bwwidth95\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Cash flow (\u20ac thousands)<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth15 bwvertalignb bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>FY 2025<\/b><\/p>\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth15 bwvertalignb bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>FY 2024<\/b><\/p>\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOperating cash flow<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(14,728)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(18,909)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nChange in operating working capital requirement<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(1,035)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1,084<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet cash flow from operating activities<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(17,426)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(17,949)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet cash flow from investing activities<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(824)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(1,167)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet cash flow from financing activities<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n28,433<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n7,666<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nImpact of changes in exchange rates<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(97)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n83<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet change in cash and cash equivalents<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n10,086<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(11,367)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCash and cash equivalent at end of period<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n18,214<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n8,128<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<ul class=\"bwlistdisc\">\n<li>\nCash and cash equivalents at end of period totaled \u20ac18.2 million, compared to \u20ac8.1 million at end-2024.<\/li>\n<li>\nOperating Cash Flow consumption decreased from \u20ac18.9 million in 2024 to \u20ac14.7 million in 2025, driven by the reduction of operating losses.<\/li>\n<li>\nThe Company completed several cash injections for a total amount of \u20ac29.7 million gross proceeds, including:<\/li>\n<\/ul>\n<ul class=\"bwlistdisc bwmarginl2\">\n<li>\nDrawdown of an equity line of \u20ac4.0 million in January 2025,<\/li>\n<li>\nCash proceeds of \u20ac21.8 million in August 2025, as part a \u20ac23.9 million gross capital increase through the issuance of ABSA (shares with warrants attached),<\/li>\n<li>\nExercise of warrants for an exercise value of \u20ac3.9 million in HY2.<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nMoreover, a new \u20ac37.5 million financing facility from the European Investment Bank signed <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmediantechnologies.com%2Finvestors%2Fpress-releases%2Fmedian-technologies-signs-financial-agreement-for-up-to-e37-5-million-new-financing-facility-with-the-european-investment-bank-eib%2F&amp;esheet=54521559&amp;newsitemid=20260423130605&amp;lan=en-US&amp;anchor=on+July+11%2C+2025&amp;index=6&amp;md5=09f8fc25ebb02d2ca67c1ff35654ace4\" rel=\"nofollow\" shape=\"rect\">on July 11, 2025<\/a>, with the first \u20ac19 million tranche drawn on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmediantechnologies.com%2Finvestors%2Fpress-releases%2Fmedian-technologies-receives-e19-million-from-the-european-investment-bank-corresponding-to-the-first-tranche-under-the-2025-loan-facility%2F&amp;esheet=54521559&amp;newsitemid=20260423130605&amp;lan=en-US&amp;anchor=October+21%2C+2025&amp;index=7&amp;md5=88d8750e83ad8948be2782a0de1d805f\" rel=\"nofollow\" shape=\"rect\">October 21, 2025<\/a>, following the \u20ac20.7 million repayment of the 2019 EIB loan tranche on October 17, 2025.<\/li>\n<\/ul>\n<p>\n<b>Net income statement under IFRS accounting rules<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwwidth90 bwblockalignc\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>\u20ac thousands<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth15 bwvertalignb bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>FY 2025<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth15 bwvertalignb bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>FY 2024<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRevenue<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n23,359<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n22,948<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIncome from ordinary activities<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n23,469<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n22,960<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nStaff costs<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(19,737)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(23,807)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nExternal costs<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(17,280)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(20,212)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOperating profit (loss)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(16,266)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(22,533)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet financial income<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(17,656)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(2,564)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet profit (loss)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(34,069)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(25,240)<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<ul class=\"bwlistdisc\">\n<li>\nMedian\u2019s 2025 revenue was generated entirely by its iCRO Business Unit, which provides advanced imaging services to assess drug efficacy in industry\u2011sponsored oncology clinical trials. Full\u2011year 2025 revenue amounted to \u20ac23.4 million, representing a 2.2% increase compared to \u20ac22.9 million in 2024.<\/li>\n<li>\nStaff costs decreased by \u20ac4.1 million year over year, declining from \u20ac23.8 million in 2024 to \u20ac19.7 million in 2025. This reduction reflects lower share\u2011based compensation expenses as well as a decrease in full\u2011year payroll costs, primarily driven by efficiency initiatives implemented to improve iCRO profitability. The Company\u2019s average headcount decreased from 241 employees in 2024 to 208 in 2025.<\/li>\n<li>\nExternal expenses declined by \u20ac2.9 million compared to 2024, primarily driven by targeted optimization of iCRO\u2011related costs, including image reader services, data transfer, and server hosting expenses.<\/li>\n<li>\nOverall, operating loss decreased by 27.6% year over year, from \u20ac22.5 million in 2024 to \u20ac16.3 million in 2025, reflecting the Company\u2019s sustained focus on cost discipline and operational efficiency.<\/li>\n<li>\nNet financial income was negative in 2025 at \u20ac17.7 million, primarily due to a \u20ac13.2 million non\u2011cash impact related to the change in fair value of the EIB warrants. Additional negative financial income resulted from higher interest and financial charges totaling \u20ac1.8 million, related to the EIB Tranche B financing and the Celestial Successor Fund (CSF) bonds.<\/li>\n<li>\nAs a result, net loss increased by \u20ac8.83 million in 2025 compared to 2024, primarily driven by non\u2011cash financial items.<\/li>\n<\/ul>\n<p>\n<strong>2025 operational highlights<\/strong><\/p>\n<p>\n2025 operational highlights were published on<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmediantechnologies.com%2Finvestors%2Fpress-releases%2Fmedian-technologies-reports-landmark-2025-performance-with-major-regulatory-and-commercial-milestones-ahead-in-2026%2F&amp;esheet=54521559&amp;newsitemid=20260423130605&amp;lan=en-US&amp;anchor=January+19%2C+2026&amp;index=8&amp;md5=80569c367e4d0b0c4282523a83aa3636\" rel=\"nofollow\" shape=\"rect\"> January 19, 2026<\/a><strong>.<\/strong><\/p>\n<p class=\"bwalignc\">\nMedian Technologies informs its shareholders and the financial community that its annual financial report on the accounts for the year ended December 31, 2025, has been made available and filed with the French financial market authority (Autorit\u00e9 des March\u00e9s Financiers).<br \/>\n<br \/>The annual financial report is available on the Company\u2019s website: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmediantechnologies.com%2Finvestors%2Ffinancial-results-and-reports%2F&amp;esheet=54521559&amp;newsitemid=20260423130605&amp;lan=en-US&amp;anchor=https%3A%2F%2Fmediantechnologies.com%2Finvestors%2Ffinancial-results-and-reports%2F&amp;index=9&amp;md5=8b73797671bbb1e47945580d6390afa1\" rel=\"nofollow\" shape=\"rect\">https:\/\/mediantechnologies.com\/investors\/financial-results-and-reports\/<\/a><\/p>\n<p>\n<b>About Median Technologies: <\/b>Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median&#8217;s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis\u00ae, an AI\/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mediantechnologies.com&amp;esheet=54521559&amp;newsitemid=20260423130605&amp;lan=en-US&amp;anchor=www.mediantechnologies.com&amp;index=10&amp;md5=43250ebdd249c8fcff6597fffe7c42d0\" rel=\"nofollow\" shape=\"rect\">www.mediantechnologies.com<\/a>.<\/p>\n<p>\n<b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements. These statements are not historical facts. They include projections and estimates as well as the assumptions on which these are based, statements concerning projects, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, or future performance.<\/p>\n<p>\nThese forward-looking statements can often be identified by the words &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;estimates&#8221; or &#8220;plans&#8221; and any other similar expressions. Although Median&#8217;s management believes that these forward-looking statements are reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median Technologies, that could cause actual results and events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.<\/p>\n<p>\nAll forward-looking statements in this press release are based on information available to Median Technologies as of the date of the press release. Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Autorit\u00e9 des March\u00e9s Financiers.<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n____________________<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<sup>1<\/sup> The order backlog is the sum of orders received but not yet fulfilled. An increase or decrease in the order backlog corresponds to the order intake of the reporting period, net of invoiced services, completed or cancelled contracts, and currency impact for projects in foreign currency (re-evaluated at the exchange rate on closing date). Orders are booked once the customer confirms, in writing, its retention of the Company\u2019s services for a given project. The contract is usually signed a few months after written confirmation.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n\u00a0<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>MEDIAN TECHNOLOGIES<\/b><br \/><b>Emmanuelle Leygues<\/b><br \/>VP, Corporate Marketing &amp; Financial Communications<br \/>\n<br \/>+33 6 10 93 58 88<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#58;&#101;&#109;&#109;anue&#x6c;&#x6c;&#x65;&#x2e;&#x6c;&#x65;&#121;&#103;&#117;&#101;&#115;&#64;me&#x64;&#x69;&#x61;&#x6e;&#x74;&#x65;&#99;&#104;&#110;&#111;&#108;ogi&#x65;&#x73;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x65;&#x6d;&#109;a&#x6e;&#x75;&#101;ll&#x65;&#x2e;&#108;e&#x79;&#x67;&#117;&#101;s&#x40;&#x6d;&#101;d&#x69;&#x61;&#110;&#116;e&#x63;&#x68;&#110;o&#x6c;&#x6f;&#103;&#105;e&#x73;&#x2e;&#99;o&#x6d;<\/a><\/p>\n<p><b>Investors &#8211; SEITOSEI ACTIFIN<\/b><br \/><b>Ghislaine Gasparetto<\/b><br \/>+33 6 85 36 76 81<br \/>\n<br \/><a target=\"_blank\" href=\"mailto:ghislaine&#46;gaspare&#116;&#116;&#111;&#64;&#115;&#101;&#105;&#116;&#111;&#115;&#101;&#105;&#45;&#97;&#99;&#116;&#105;&#102;&#105;&#110;&#46;&#99;&#111;&#109;\" rel=\"nofollow\" shape=\"rect\">&#x67;&#x68;&#x69;&#x73;&#x6c;&#x61;&#x69;&#x6e;&#x65;&#x2e;&#x67;&#x61;&#x73;&#x70;&#x61;&#x72;&#x65;&#x74;&#x74;&#x6f;&#x40;&#x73;&#x65;&#x69;&#x74;&#x6f;&#x73;&#x65;&#x69;&#x2d;&#x61;&#x63;&#x74;&#x69;&#x66;&#x69;&#x6e;&#x2e;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<p><b>Press \u2013 MAARC<\/b><br \/><b>Bruno Arabian<\/b><br \/>+33 6 87 88 47 26<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;t&#x6f;&#58;&#x62;&#114;u&#x6e;&#111;&#x2e;&#97;r&#x61;&#98;&#x69;&#x61;n&#x40;&#109;a&#x61;&#114;&#x63;&#46;f&#x72;\" rel=\"nofollow\" shape=\"rect\">brun&#111;&#46;&#97;&#114;&#97;&#98;&#105;&#x61;&#x6e;&#x40;&#x6d;&#x61;&#x61;&#x72;&#x63;&#x2e;fr<\/a><\/p>\n<p><b>U.S. media \u2013 TODD STEIN COMMUNICATIONS<\/b><br \/><b>Todd Stein<\/b><br \/>+1 510.417.0612<br \/>\n<br \/><a target=\"_blank\" href=\"mai&#108;&#116;&#111;&#x3a;&#x74;&#x6f;&#x64;&#x64;&#x40;tod&#100;&#115;&#116;&#101;&#x69;&#x6e;&#x63;&#x6f;&#x6d;&#x6d;uni&#99;&#97;&#116;&#x69;&#x6f;&#x6e;&#x73;&#x2e;&#x63;om\" rel=\"nofollow\" shape=\"rect\">&#x74;&#x6f;&#x64;&#100;&#64;&#116;od&#x64;&#x73;&#x74;&#x65;&#105;&#110;co&#x6d;&#x6d;&#x75;&#x6e;&#105;&#99;at&#x69;&#x6f;&#x6e;&#x73;&#46;&#99;&#111;m<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>eyonis\u00ae LCS 510(k) clearance sets stage for commercialization in the United States New leadership of U.S. subsidiary and collaboration with Tempus accelerate rollout 28% reduction in operating loss in 2025 year\u2011over\u2011year, demonstrating strengthened cost discipline and operational efficiency iCRO order backlog reaches a new record at \u20ac79.8 million as of March 31, 2026 Cash and &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62994","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"eyonis\u00ae LCS 510(k) clearance sets stage for commercialization in the United States New leadership of U.S. subsidiary and collaboration with Tempus accelerate rollout 28% reduction in operating loss in 2025 year\u2011over\u2011year, demonstrating strengthened cost discipline and operational efficiency iCRO order backlog reaches a new record at \u20ac79.8 million as of March 31, 2026 Cash and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T17:02:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260423130605\/en\/2783697\/22\/Logo_Median.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights\",\"datePublished\":\"2026-04-23T17:02:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\\\/\"},\"wordCount\":2437,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260423130605\\\/en\\\/2783697\\\/22\\\/Logo_Median.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\\\/\",\"name\":\"Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260423130605\\\/en\\\/2783697\\\/22\\\/Logo_Median.jpg\",\"datePublished\":\"2026-04-23T17:02:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260423130605\\\/en\\\/2783697\\\/22\\\/Logo_Median.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260423130605\\\/en\\\/2783697\\\/22\\\/Logo_Median.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/","og_locale":"en_US","og_type":"article","og_title":"Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights - Pharma Trend","og_description":"eyonis\u00ae LCS 510(k) clearance sets stage for commercialization in the United States New leadership of U.S. subsidiary and collaboration with Tempus accelerate rollout 28% reduction in operating loss in 2025 year\u2011over\u2011year, demonstrating strengthened cost discipline and operational efficiency iCRO order backlog reaches a new record at \u20ac79.8 million as of March 31, 2026 Cash and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/","og_site_name":"Pharma Trend","article_published_time":"2026-04-23T17:02:23+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260423130605\/en\/2783697\/22\/Logo_Median.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights","datePublished":"2026-04-23T17:02:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/"},"wordCount":2437,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260423130605\/en\/2783697\/22\/Logo_Median.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/","url":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/","name":"Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260423130605\/en\/2783697\/22\/Logo_Median.jpg","datePublished":"2026-04-23T17:02:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260423130605\/en\/2783697\/22\/Logo_Median.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260423130605\/en\/2783697\/22\/Logo_Median.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62994"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62994\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}